| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 137 |
| 性別 | 男女 |
| 年齢 | 45-64 |
| 体型 | 肥満 |
この研究の注釈：
Supplementation of 1mg chromium (in the form of chromium picolinate) in two divided doses daily for 24 weeks in type II diabetics noted that while there was a trend to increase insulin sensitivity, this was not statistically significant and only 46% of persons were considered responders.
Supplementation of 1mg chromium (in the form of chromium picolinate) in two divided doses daily for 24 weeks in type II diabetics noted that while there was a trend to increase insulin sensitivity, this was not statistically significant and only 46% of persons were considered responders.
No other changes were noted in diet, glucose metabolism, and the response to chromium was more associated with baseline insulin resistance rather than the kinetics of chromium after ingestion.
Effects Of Chromium Picolinate On Food Intake And Satiety
| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 42 |
| 性別 | 女性 |
| 年齢 | 18-29 |
| 体型 | 肥満 |
この研究の注釈：
In overweight women reporting intense carbohydrate cravings at least twice a week, supplementation of 1,000mcg chromium appeared to reduce hunger and cravings over the course of weight weeks which resulted in a greater reduction in overall food intake (25%) than did placebo (8%). This reduction in food intake led to weight loss, but was independent of any changes in glucose metabolism.
A Double-blind, Placebo-controlled, Exploratory Trial Of Chromium Picolinate In Atypical Depression: Effect On Carbohydrate Craving
| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 75 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
| 体型 | 肥満, 肥満 |
この研究の注釈：
In adult outpatients with atypical depression given 600mcg chromium (as picolinate) daily over the course of eight weeks, supplementation failed to outperform placebo in the primary intention to treat (overall depressive symptoms as assessed by HAM-D) but when assessing the parameters associated with food intake and carbohydrate cravings chromium appeared to outperform placebo by reducing cravings and food consumption.
In adult outpatients with atypical depression given 600mcg chromium (as picolinate) daily over the course of eight weeks, supplementation failed to outperform placebo in the primary intention to treat (overall depressive symptoms as assessed by HAM-D) but when assessing the parameters associated with food intake and carbohydrate cravings chromium appeared to outperform placebo by reducing cravings and food consumption.
In persons with high baseline carbohydrate cravings, there was also an improvement in genital symptoms (ie. libido) relative to placebo.
